Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other financing activities (2018 - 2022)

Historic Other financing activities for OptimizeRx (OPRX) over the last 10 years, with Q3 2022 value amounting to $4.3 million.

  • OptimizeRx's Other financing activities rose 32432.65% to $4.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $10.1 million, marking a year-over-year increase of 22607.86%. This contributed to the annual value of $1.9 million for FY2018, which is N/A changed from last year.
  • According to the latest figures from Q3 2022, OptimizeRx's Other financing activities is $4.3 million, which was up 32432.65% from $4.0 million recorded in Q2 2022.
  • OptimizeRx's 5-year Other financing activities high stood at $4.3 million for Q3 2022, and its period low was $408087.0 during Q2 2019.
  • In the last 5 years, OptimizeRx's Other financing activities had a median value of $754512.0 in 2020 and averaged $1.3 million.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 1341.42% in 2021, then soared by 42145.07% in 2022.
  • Quarter analysis of 5 years shows OptimizeRx's Other financing activities stood at $1.0 million in 2018, then plummeted by 54.34% to $469539.0 in 2019, then surged by 34.48% to $631453.0 in 2020, then skyrocketed by 59.63% to $1.0 million in 2021, then soared by 324.33% to $4.3 million in 2022.
  • Its Other financing activities was $4.3 million in Q3 2022, compared to $4.0 million in Q2 2022 and $1.0 million in Q3 2021.